Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC

This is a prospective, single-arm, exploratory clinical study enrolling patients with resectable, locally advanced thoracic esophageal squamous cell carcinoma (ESCC) confirmed by histology or cytology. The study aims to evaluate the efficacy and safety of neoadjuvant therapy with adebrelimab in combination with famitinib and chemotherapy in this population. The primary endpoint is the pathological complete response (pCR) rate, with a planned enrollment of 24 patients.

Trial Details

NCT ID
NCT07796113
Phase
PHASE2
Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Status
RECRUITING
Cancer Type
Squamous Cell Esophageal Cancer
Interventions
  • Adebrelimab + Famitinib + Chemotherapy
Locations (sample)
  • Xi'an, Shannxi, China|34.25833,108.92861

Key Eligibility Criteria

  • Signed written informed consent and voluntarily agrees to participate in the study.
  • Histologically or cytologically confirmed esophageal squamous cell carcinoma (ESCC).
  • Thoracic esophageal cancer evaluated by CT, MRI, or EUS, with clinical stage T1b-T2N+ or T3-T4a, any N (according to the AJCC 8th edition).
  • Expected to achieve R0 resection after neoadjuvant therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Esophageal Cancer Trials on Trialify →